Global Venous Leg Ulcer Market - 2023-2030

Global Venous Leg Ulcer Market - 2023-2030

Global Venous Leg Ulcers Treatment Market reached US$ XX million in 2022 and is expected to reach US$ XX million by 2030, growing with a CAGR of XX % during the forecast period 2023-2030.

Venous Leg Ulcers Treatment (VLUs) are late indicators of chronic venous insufficiency (CVI) and venous hypertension. In normal conditions, calf muscle contraction and intraluminal valves promote prograde flow while preventing blood reflux. However, when retrograde flow, obstruction, or both exist, the resultant chronic venous hypertension is responsible for the dermatologic and vascular complications that culminate in the formation of a VLU.

Although CVI is a well-known precipitant for VLU development, ulceration occurs rarely (5.1%) for unclear reasons. CVI may develop due to blood reflux, obstruction, or a combination of both mechanisms, causing macro- and micro-circulatory dysfunction. The increased intraluminal pressure causes protein extravasation and fibrin cuff formation, which impedes the diffusion of oxygen and growth factors, and also activates the inflammatory response.

Market Dynamics: Drivers and Restraints

Rise in technological advancements

Growing advancements in treatment therapy are anticipated to play a vital role in fueling venous leg ulcer treatment market growth during the forecast period. Traditional treatment options have been evolved into multi-component and two-layer compression therapy systems or short-stretch compression therapy systems. This has advanced the ease of bandage application for clinicians while providing them with products that deliver effective therapeutic compression and is expected to boost the market growth.

For instance, negative pressure wound therapy is one of the technologies used in venous leg ulcer treatment. Negative pressure wound therapy (NPWT) is a technology supporting the standard of care in VLUs. NPWT accelerates the healing process of venous leg ulcers with several mechanisms such as local edema reduction, reduction in bacteria, inflammatory mediators, and wound exudate.

Also, researchers at RMIT University and Bolton Clarke Research Institute have developed an AI-powered tool to screen for chronic wounds, enabling nurses to identify these hard-to-heal sores during the first assessment at a person's home. This breakthrough is significant as it allows for the identification of wounds a week earlier, a significant leap forward for the Australian health system. The tool is not sensitive to changes in ambient temperature and light, making it suitable for regular home visits and tropical environments.

Furthermore, the market is also driven by other factors like increasing adoption of compression therapy, rise in the prevalence of venous leg ulcers and others will further drive the market during the forecast period.

Market Dynamics: Restraint

The high cost of treatment is one of the major factors that hamper the market growth. For instance, according to articles published in NCBI in the USA the treatment cost of venous leg ulcers treatment is $15,732 and in the UK s £7,706 per patient per annum, which translates to an annual cost of over £2 billion, when extrapolated to UK population. Comparatively in USA, the treatment cost is higher due to a high number of populations, and improved healthcare infrastructure leads to higher costs.

Furthermore, lack of awareness, limited reimbursement, ageing population, complexity of wound care, regulatory challenges and others are also factors that hamper the market growth rate during the forecast period.

Segment Analysis

The global venous leg ulcers treatment market is segmented based on treatment type, sales channel and region.

The compression therapy segment from the treatment type segment accounted for approximately 41.7% venous leg ulcers treatment market share

The compression therapy segment from the treatment type segment accounted for approximately 41.7% and it is expected to be dominated during the forecast period. Compression therapy helps increase blood circulation in the lower legs, ankles and feet. It is an effective treatment for pain and swelling caused by conditions associated with poor circulation, such as chronic venous insufficiency and varicose veins. There are many types of compression therapy devices available over the counter or with a prescription.

For instance, in February 2021, Researchers from Tyndall National Institute at UCC; together with researchers from RCSI, University of Medicine and Health Sciences; multinationals DeRoyal Global Healthcare Solutions and Henkel launched a €1 million Enterprise Ireland Innovation Partnership collaboration to innovate the next generation of compression wound care therapy.

Non-healing chronic wounds affect more than 5% of us, with numbers rising due to growing elderly and diabetic populations. These wounds cause significant morbidity and mortality, leading to €12.5 billion in worldwide healthcare costs annually. In some regions of the world, a patient loses a diabetic foot to amputation every 12 seconds.

Geographical Analysis

North America accounted for approximately 38.4% of the market share in 2022

North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to the novel launches, rise in prevalence of venous leg ulcer cases in the U.S and Canada, rise in R&D for the development of newer products, and favourable reimbursement policies bolster the market.

For instance, in April 2022 Koya Medical stated that it commercially launched its Dayspring active compression system in the U.S. Oakland, California-based Koya designed the wearable Dayspring compression system to treat lymphedema and venous leg diseases in the lower extremities. It features a soft, breathable mesh garment with Koya’s proprietary Flexframe — spring-like segments for delivering compression — technology.

Koya said Dayspring for the upper extremity has been commercially available since 2021. Its expansion into lower extremity care (available in both full and lower leg applications) allows the company to better support people with lymphedema and venous diseases.

COVID-19 Impact Analysis

The COVID-19 pandemic has exacerbated the challenge of treating nonhealing vascular ulcers due to lack of multidisciplinary treatment, reduced healthcare resources, and restrictions. This has led to increased morbidity and amputation rates. Training patients in self-care and triage can improve outcomes, even with telemedicine. Governments, scientific committees, and healthcare officials should focus on protecting vulnerable patients during biological storms.

Market Segmentation

By Treatment Type
• Compression Therapy
• Advanced Wound Dressings
• Debridement
• Medications
• Others

By Sales Channel
• End User
Hospitals
Speciality Clinics
Home care Services
Others
• Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
UK
France
Italy
Spain
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Competitive Landscape

The major global players in the market include 3M, Integra Life Sciences Corporation, Smith and Nephew, Urgo Medical, Paul Hartmann, Bauerfeind Canada - Medical., Cardinal Health, Medline, Essity, Medi GmbH & Co. KG and among others.

Key Developments

In June 2023 JeNaCell, an Evonik company, launched the wound dressing epicite balance onto the German market. Available from June 2023, the dressing is particularly suited and optimized for the treatment of chronic wounds with low to medium exudation, such as venous leg ulcers, arterial leg ulcers, diabetic foot ulcers, pressure ulcers and soft tissue lesions.epicite balance comes in three different sizes and will be distributed through the company Coopmed ApS to hospitals and homecare centres.

In January 2023, MiMedx Group, Inc. entered into an exclusive distribution agreement with GUNZE MEDICAL LIMITED for the sales of EPIFIX in Japan. EPIFIX is a PURION-processed placental tissue allograft that supports the healing cascade by providing a semi-permeable, protective barrier over wounds.

Why Purchase the Report?
• To visualize the global venous leg ulcers treatment market segmentation based on treatment type, sales channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of venous leg ulcer treatment market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global venous leg ulcers treatment market report would provide approximately 69 tables, 58 figures and 187 Pages.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies